Study and population characteristics
| Study . | Setting . | Period . | Age limits, (mean, y) . | Total, N . | Type A, n . | Type B, n . | Disease severity, n (%) . | Proph. n (%) . | Inhib. n (%) . | HIV+ n (%) . | HCV+ n (%) . | Study details . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe . | Moderate . | Mild . | ||||||||||||
| Lifetime | ||||||||||||||
| Khair et al54 | AHEAD* | 2011-2016 | No (21) | 522 | 522 | 0 | 299 (57) | 221 (42) | 0 | 406 (78) | 22 (4) | NR | NR | Prospective multicenter postauthorization study, patient diaries |
| Zanon et al19 | Italy | 1987-2008 | No | 3683 | NR | NR | NR | NR | NR | NR | NR | NR | NR | Survey among HTCs over 1987-2008, prospective follow-up over 2003-2008 |
| Fransen van de Putte et al18 | Netherlands | ≤2010 | ≥18 y (54) | 408 | 365 | 43 | 204 (50) | 204 nonsevere (50) | NR | NR | 49 (12) | 229 (56) | Retrospective single-center study | |
| Loomans et al8 | INSIGHT† | 1980-2010 | No | 2709 | 2709 | 0 | 0 | 719 (27) | 1990 (73) | NR | NR | NR | NR | Retrospective multicenter study |
| Koumbarelis et al41 | Greece | 1972-1993 | No | 531 | 460 | 71 | 319 (60) | 92 (17) | 227 (43) | 0 | 38 (7) | 156 (29) | NR | Single-center registry |
| Plug et al45 | Netherlands | 1992-2001 | No (32) | 967 | 796 | 171 | 386 (40) | 167 (17) | 414 (43) | NR | 50 (5) | 53 (5) | NR | National survey, medical files and municipal registries |
| Rosendaal et al44 | Netherlands | 1973-1986 | No (23) | 717 | 616 | 101 | 321 (45) | 169 (24) | 227 (32) | 129 (18) | 30 (4) | NR | NR | National survey, medical files and municipal registries |
| Triemstra et al46 | Netherlands | 1986-1992 | No (30) | 919 | 796 | 123 | 381 (41) | 172 (19) | 366 (40) | 200 (22) | 22 (2) | 35 (4) | NR | National survey, medical files and municipal registries |
| Nuss et al21 | USA | 1993-1997 | No | 3269 | 2579 | 690 | 1371 (42) | 779 (24) | 1028 (31) | 82 (3) | 146 (4) | 827 (25) | 1346 (41) | Case-control in HSS database, ICD codes & medical files |
| Yoo et al55 | Korea | 1991-2012 | No | 2048 | 1675 | 373 | 1354 (66) | 452 (22) | 226 (11) | NR | 79 (4) | 25 (1) | NR | National registry |
| Darby et al14 | UK | 1977-1998 | <85 y | 6018 | 4874 | 1144 | 1320 (22) | 1476 (25) | 3222 (54) | NR | NR | 0 | NR | UKHCDO, all patients registered at UK HTCs |
| Witmer et al22 | USA | 1998-2008 | >2 y | 10 262 | 8087 | 2175 | 5581 (54) | 2398 (24) | 2283 (22) | 3052 (30) | 586 (6) | 1311 (13) | 4107 (40) | Prospective case-control UDC database |
| Shih et al56 | Taiwan | 1997-2013 | No (33) | 795 | 658 | 137 | 795 (100) | 0 | 0 | NR | 0 | 218 (27) | 29 (4) | Retrospective national insurance database |
| Fransen van de Putte et al57 | Netherlands & UK | ≤2011 | ≥30 y (50) | 709 | 594 | 113 | 344 (48) | 365 nonsevere (52) | 223 (31) | NR | 76 (11) | 228 (32) | Retrospective study into lifetime CVD events of a living cohort | |
| Lövdahl et al58 | Sweden | 1968-2009 | No | 1431 | NR | NR | 384 (41) | 145 (16) | 405 (43) | NR | NR | 96 (7) | NR | Hemophilia registry and death, migration, and medical birth registries, ICD codes |
| Reitter et al59 | Austria | 1983-2006 | No (28) | 226 | 207 | 19 | 128 (57) | 14 (6) | 84 (37) | NR | 21 (9) | 74 (33) | 136 (60) | Retrospective survival analysis, death registry, medical files, ICD codes |
| Sharathkumar et al60 | USA | ≤2008 | ≥35 y (53) | 185 | 102 | 83 | 47 (25) | 57 (31) | 81 (44) | 0 | 8 (4) | 27 (15) | 125 (68) | Retrospective study into lifetime CVD events of a living cohort |
| Rizza and Spooner61 | UK | 1976-1980 | <85 y | 5098 | 4321 | 777 | 2179 (43) | 2491 nonsevere (49) | NR | 265 (5) | NR | NR | UKHCDO, all patients registered at UK HTCs | |
| Rizza et al62 | UK | 1981-1996 | <85 y | 5890 | 4826 | 1064 | 1878 (32) | 3723 nonsevere (63) | NR | 261 (4) | NR | NR | UKHCDO, all patients registered at UK HTCs | |
| Kim et al63 | Korea | ≤1987 | No | 498 | 425 | 73 | 273 (55) | 182 (37) | 43 (9) | NR | NR | 2 (0) | 11 (3) | Survey among all HTCs in Korea |
| Chuansumrit et al20 | Thailand | 1971-2000 | No (17) | 164 | 138 | 26 | 64 (39) | 81 (49) | 19 (16) | 0 | NR | 7 (1) | 43 (26) | Retrospective survival analysis |
| Okolo et al64 | USA | ≤2013 | No (30) | 704 | 456 | 248 | 233 (33) | 185 (26) | 267 (38) | 201 (29) | 16 (2) | 28 (4) | 134 (19) | Surveillance study (IHSS), vital statistics, medical files, birth registry, claims |
| Fukutake et al65 | Japan | 2007-2012 | ≥1 y (26) | 352 | 352 | 0 | 266 (76) | 63 (18) | 21 (6) | 195 (55) | 9 (3) | NR | NR | Retrospective and prospective multicenter postauthorization study |
| Children and young adults | ||||||||||||||
| Andersson et al3 | PedNet‡ | 2011-2015 | 1 mo to 22 y (9) | 1515 | 1250 | 265 | 1515 (100) | 0 | 0 | NR | 0 | NR | NR | Registry with 5-y retrospective data and 4-y prospective data (2011-2015) |
| Traivaree et al23 | Canada | 1996-2004 | 1 mo to 18 y (10) | 275 | 218 | 57 | 116 (42) | 159 nonsevere (58) | 88 (32) | 12 (4) | NR | NR | Retrospective single-center study | |
| Hu et al24 | China | 2009-2014 | Children | 126 | 126 | 0 | 42 (33) | 64 (51) | 20 (16) | 36 (29) | 2 (2) | NR | NR | Retrospective study of all patients receiving treatment during study period |
| Haque et al66 | China | 2005-2017 | Children | 226 | 170 | 56 | 91 (40) | 88 (39) | 47 (21) | NR | 9 (0) | NR | NR | Retrospective single-center study |
| Loomans et al8 | INSIGHT† | 1980-2010 | ≤19 y | NR | NR | 0 | 0 | NR | NR | NR | NR | NR | NR | Retrospective multicenter study |
| Darby et al14 | UK | 1977-1998 | ≤24 y | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | UKHCDO, all patients registered at UK HTCs |
| Chalmers et al6 | UK | 2003-2015 | ≤16 y | 1321 | 1096 | 225 | 655 (50) | 666 nonsevere (50) | NR | NR | NR | NR | UKHCDO, retrospective study of database | |
| Bladen et al17 | UK | 1987-2013 | Children | 431 | 364 | 67 | 283 (66) | 34 (8) | 107 (25) | NR | NR | NR | NR | Retrospective single-center study |
| Revel-Vilk et al16 | Canada | 1984-2000 | ≤18 y (9§) | 172 | NR | NR | NR | NR | NR | NR | 0 | NR | NR | Retrospective study into lifetime ICH of a living cohort |
| Carneiro et al67 | Brazil | NR | NR (13) | 50 | 38 | 12 | 35 (70) | 15 (30) | 0 | 33 (66) | 5 (10) | NR | NR | Cross-sectional random sample of a living cohort with retrospective ICH assessment |
| Canada | NR (12) | 50 | 41 | 9 | 35 (70) | 15 (30) | 0 | 38 (76) | 6 (12) | |||||
| Nelson et al68 | USA | 1989-1994 | ≤19 y (12§) | 309ǁ | 273 | 50 | 246 (74) | 63 (19) | 23 (7) | NR | NR | 207 (67) | NR | Retrospective study of living children enrolled in HGDS study |
| Poonnoose et al69 | Musfih¶ | 2005-2010 | 5-17 y | 255 | 220 | 35 | 255 (100) | 0 | 0 | 39 (15) | 0 | NR | NR | Prospective multicenter study |
| Klinge et al15 | Germany | 1975-1998 | Children | 744 | 602 | 142 | 507 (68) | 235 nonsevere (32) | NR | NR | NR | NR | Survey among HTCs over children born 1975-1997, retrospective ICH assessment | |
| Meunier et al70 | France | <2012 | ≤25 y | 209 | 183 | 26 | 171 (82) | 38 (18) | 0 | 169 (81) | 0 | NR | NR | Retrospective multicenter study of a living cohort |
| Öner et al71 | Turkey | 1985-2017 | <18 y | 135 | 113 | 22 | 64 (47) | 41 (30) | 30 (22) | NR | 17 (13) | NR | NR | Retrospective single-center study |
| Kulkarni et al25 | USA | 2004-2011 | <2 y | 547 | 450 | 97 | 326 (60) | 131 (24) | 89 (16) | NR | 109 (20) | NR | NR | UDC database enrolling babies with ≥1 visit between 24 and 30 mo of age |
| Neonates | ||||||||||||||
| Ljung et al26 | Sweden | 1970-1990 | Perinatal | 117 | 101 | 16 | 89 (76) | 28 (24) | 0 | NR | NR | NR | NR | National retrospective analysis |
| MacLean et al72 | Netherlands | 1985-2002 | Postnatal | 73 | 60 | 13 | 25 (34) | 9 (12) | 39 (53) | NR | NR | NR | NR | Retrospective analysis of a living cohort |
| Kenet et al27 | USA | 2003-2010 | <1 mo | 633 | NR | NR | NR | NR | NR | NR | 5 (1) | NR | NR | UDC database enrolling babies diagnosed within 1 mo of age |
| Richards et al28 | EHTSB# | 1990-2008 | ≤28 d | 508 | 429 | 78 | 257 (51) | 101 (20) | 149 (29) | NR | NR | NR | NR | Retrospective multicenter study |
| Nazir et al29 | Gulf region** | 1998-2015 | <2 wk | 163 | 163 | 0 | 163 (100) | 0 | 0 | NR | NR | NR | NR | Study with retrospective data (1998-2013) and prospective data (2013-2015) |
| Palomo Bravo et al73 | Spain | 2000-2012 | Perinatal | 88 | 80 | 8 | 42 (48) | 12 (14) | 34 (39) | NR | NR | NR | NR | Retrospective study of consecutively born children followed up for ≥1 y |
| Andersson et al30 | PedNet†† | 2000-2015 | ≤28 d | 926 | 803 | 123 | 786 (85) | 140 (15) | 0 | NR | NR | NR | NR | Prospective study of children consecutively born with ≥1 follow-up visit |
| Yoffe and Buchanan74 | USA | 1977-1987 | Neonatal | 150 | 119 | 31 | NR | NR | NR | NR | NR | NR | NR | Retrospective analysis of a living cohort |
| Klinge et al15 | Germany | 1975-1997 | <1 wk | 744 | 602 | 142 | 507 (68) | 129 (17) | 108 (15) | NR | NR | NR | NR | Survey among HTCs over children born 1975-1997, retrospective ICH assessment |
| Revel-Vilk et al16 | Canada | 1984-2000 | <1 mo | 172 | NR | NR | NR | NR | NR | NR | NR | NR | NR | Retrospective study into lifetime ICH among a living cohort |
| Bladen et al17 | UK | 1987-2013 | Neonatal | 431 | 364 | 67 | 283 (66) | 34 (8) | 107 (25) | NR | NR | NR | NR | Retrospective single-center study |
| Chalmers et al6 | UK | 2003-2015 | <1 mo | 1321 | 1096 | 225 | 655 (50) | 666 nonsevere (50) | NR | NR | NR | NR | UKHCDO, retrospective study of database | |
| Study . | Setting . | Period . | Age limits, (mean, y) . | Total, N . | Type A, n . | Type B, n . | Disease severity, n (%) . | Proph. n (%) . | Inhib. n (%) . | HIV+ n (%) . | HCV+ n (%) . | Study details . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe . | Moderate . | Mild . | ||||||||||||
| Lifetime | ||||||||||||||
| Khair et al54 | AHEAD* | 2011-2016 | No (21) | 522 | 522 | 0 | 299 (57) | 221 (42) | 0 | 406 (78) | 22 (4) | NR | NR | Prospective multicenter postauthorization study, patient diaries |
| Zanon et al19 | Italy | 1987-2008 | No | 3683 | NR | NR | NR | NR | NR | NR | NR | NR | NR | Survey among HTCs over 1987-2008, prospective follow-up over 2003-2008 |
| Fransen van de Putte et al18 | Netherlands | ≤2010 | ≥18 y (54) | 408 | 365 | 43 | 204 (50) | 204 nonsevere (50) | NR | NR | 49 (12) | 229 (56) | Retrospective single-center study | |
| Loomans et al8 | INSIGHT† | 1980-2010 | No | 2709 | 2709 | 0 | 0 | 719 (27) | 1990 (73) | NR | NR | NR | NR | Retrospective multicenter study |
| Koumbarelis et al41 | Greece | 1972-1993 | No | 531 | 460 | 71 | 319 (60) | 92 (17) | 227 (43) | 0 | 38 (7) | 156 (29) | NR | Single-center registry |
| Plug et al45 | Netherlands | 1992-2001 | No (32) | 967 | 796 | 171 | 386 (40) | 167 (17) | 414 (43) | NR | 50 (5) | 53 (5) | NR | National survey, medical files and municipal registries |
| Rosendaal et al44 | Netherlands | 1973-1986 | No (23) | 717 | 616 | 101 | 321 (45) | 169 (24) | 227 (32) | 129 (18) | 30 (4) | NR | NR | National survey, medical files and municipal registries |
| Triemstra et al46 | Netherlands | 1986-1992 | No (30) | 919 | 796 | 123 | 381 (41) | 172 (19) | 366 (40) | 200 (22) | 22 (2) | 35 (4) | NR | National survey, medical files and municipal registries |
| Nuss et al21 | USA | 1993-1997 | No | 3269 | 2579 | 690 | 1371 (42) | 779 (24) | 1028 (31) | 82 (3) | 146 (4) | 827 (25) | 1346 (41) | Case-control in HSS database, ICD codes & medical files |
| Yoo et al55 | Korea | 1991-2012 | No | 2048 | 1675 | 373 | 1354 (66) | 452 (22) | 226 (11) | NR | 79 (4) | 25 (1) | NR | National registry |
| Darby et al14 | UK | 1977-1998 | <85 y | 6018 | 4874 | 1144 | 1320 (22) | 1476 (25) | 3222 (54) | NR | NR | 0 | NR | UKHCDO, all patients registered at UK HTCs |
| Witmer et al22 | USA | 1998-2008 | >2 y | 10 262 | 8087 | 2175 | 5581 (54) | 2398 (24) | 2283 (22) | 3052 (30) | 586 (6) | 1311 (13) | 4107 (40) | Prospective case-control UDC database |
| Shih et al56 | Taiwan | 1997-2013 | No (33) | 795 | 658 | 137 | 795 (100) | 0 | 0 | NR | 0 | 218 (27) | 29 (4) | Retrospective national insurance database |
| Fransen van de Putte et al57 | Netherlands & UK | ≤2011 | ≥30 y (50) | 709 | 594 | 113 | 344 (48) | 365 nonsevere (52) | 223 (31) | NR | 76 (11) | 228 (32) | Retrospective study into lifetime CVD events of a living cohort | |
| Lövdahl et al58 | Sweden | 1968-2009 | No | 1431 | NR | NR | 384 (41) | 145 (16) | 405 (43) | NR | NR | 96 (7) | NR | Hemophilia registry and death, migration, and medical birth registries, ICD codes |
| Reitter et al59 | Austria | 1983-2006 | No (28) | 226 | 207 | 19 | 128 (57) | 14 (6) | 84 (37) | NR | 21 (9) | 74 (33) | 136 (60) | Retrospective survival analysis, death registry, medical files, ICD codes |
| Sharathkumar et al60 | USA | ≤2008 | ≥35 y (53) | 185 | 102 | 83 | 47 (25) | 57 (31) | 81 (44) | 0 | 8 (4) | 27 (15) | 125 (68) | Retrospective study into lifetime CVD events of a living cohort |
| Rizza and Spooner61 | UK | 1976-1980 | <85 y | 5098 | 4321 | 777 | 2179 (43) | 2491 nonsevere (49) | NR | 265 (5) | NR | NR | UKHCDO, all patients registered at UK HTCs | |
| Rizza et al62 | UK | 1981-1996 | <85 y | 5890 | 4826 | 1064 | 1878 (32) | 3723 nonsevere (63) | NR | 261 (4) | NR | NR | UKHCDO, all patients registered at UK HTCs | |
| Kim et al63 | Korea | ≤1987 | No | 498 | 425 | 73 | 273 (55) | 182 (37) | 43 (9) | NR | NR | 2 (0) | 11 (3) | Survey among all HTCs in Korea |
| Chuansumrit et al20 | Thailand | 1971-2000 | No (17) | 164 | 138 | 26 | 64 (39) | 81 (49) | 19 (16) | 0 | NR | 7 (1) | 43 (26) | Retrospective survival analysis |
| Okolo et al64 | USA | ≤2013 | No (30) | 704 | 456 | 248 | 233 (33) | 185 (26) | 267 (38) | 201 (29) | 16 (2) | 28 (4) | 134 (19) | Surveillance study (IHSS), vital statistics, medical files, birth registry, claims |
| Fukutake et al65 | Japan | 2007-2012 | ≥1 y (26) | 352 | 352 | 0 | 266 (76) | 63 (18) | 21 (6) | 195 (55) | 9 (3) | NR | NR | Retrospective and prospective multicenter postauthorization study |
| Children and young adults | ||||||||||||||
| Andersson et al3 | PedNet‡ | 2011-2015 | 1 mo to 22 y (9) | 1515 | 1250 | 265 | 1515 (100) | 0 | 0 | NR | 0 | NR | NR | Registry with 5-y retrospective data and 4-y prospective data (2011-2015) |
| Traivaree et al23 | Canada | 1996-2004 | 1 mo to 18 y (10) | 275 | 218 | 57 | 116 (42) | 159 nonsevere (58) | 88 (32) | 12 (4) | NR | NR | Retrospective single-center study | |
| Hu et al24 | China | 2009-2014 | Children | 126 | 126 | 0 | 42 (33) | 64 (51) | 20 (16) | 36 (29) | 2 (2) | NR | NR | Retrospective study of all patients receiving treatment during study period |
| Haque et al66 | China | 2005-2017 | Children | 226 | 170 | 56 | 91 (40) | 88 (39) | 47 (21) | NR | 9 (0) | NR | NR | Retrospective single-center study |
| Loomans et al8 | INSIGHT† | 1980-2010 | ≤19 y | NR | NR | 0 | 0 | NR | NR | NR | NR | NR | NR | Retrospective multicenter study |
| Darby et al14 | UK | 1977-1998 | ≤24 y | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | UKHCDO, all patients registered at UK HTCs |
| Chalmers et al6 | UK | 2003-2015 | ≤16 y | 1321 | 1096 | 225 | 655 (50) | 666 nonsevere (50) | NR | NR | NR | NR | UKHCDO, retrospective study of database | |
| Bladen et al17 | UK | 1987-2013 | Children | 431 | 364 | 67 | 283 (66) | 34 (8) | 107 (25) | NR | NR | NR | NR | Retrospective single-center study |
| Revel-Vilk et al16 | Canada | 1984-2000 | ≤18 y (9§) | 172 | NR | NR | NR | NR | NR | NR | 0 | NR | NR | Retrospective study into lifetime ICH of a living cohort |
| Carneiro et al67 | Brazil | NR | NR (13) | 50 | 38 | 12 | 35 (70) | 15 (30) | 0 | 33 (66) | 5 (10) | NR | NR | Cross-sectional random sample of a living cohort with retrospective ICH assessment |
| Canada | NR (12) | 50 | 41 | 9 | 35 (70) | 15 (30) | 0 | 38 (76) | 6 (12) | |||||
| Nelson et al68 | USA | 1989-1994 | ≤19 y (12§) | 309ǁ | 273 | 50 | 246 (74) | 63 (19) | 23 (7) | NR | NR | 207 (67) | NR | Retrospective study of living children enrolled in HGDS study |
| Poonnoose et al69 | Musfih¶ | 2005-2010 | 5-17 y | 255 | 220 | 35 | 255 (100) | 0 | 0 | 39 (15) | 0 | NR | NR | Prospective multicenter study |
| Klinge et al15 | Germany | 1975-1998 | Children | 744 | 602 | 142 | 507 (68) | 235 nonsevere (32) | NR | NR | NR | NR | Survey among HTCs over children born 1975-1997, retrospective ICH assessment | |
| Meunier et al70 | France | <2012 | ≤25 y | 209 | 183 | 26 | 171 (82) | 38 (18) | 0 | 169 (81) | 0 | NR | NR | Retrospective multicenter study of a living cohort |
| Öner et al71 | Turkey | 1985-2017 | <18 y | 135 | 113 | 22 | 64 (47) | 41 (30) | 30 (22) | NR | 17 (13) | NR | NR | Retrospective single-center study |
| Kulkarni et al25 | USA | 2004-2011 | <2 y | 547 | 450 | 97 | 326 (60) | 131 (24) | 89 (16) | NR | 109 (20) | NR | NR | UDC database enrolling babies with ≥1 visit between 24 and 30 mo of age |
| Neonates | ||||||||||||||
| Ljung et al26 | Sweden | 1970-1990 | Perinatal | 117 | 101 | 16 | 89 (76) | 28 (24) | 0 | NR | NR | NR | NR | National retrospective analysis |
| MacLean et al72 | Netherlands | 1985-2002 | Postnatal | 73 | 60 | 13 | 25 (34) | 9 (12) | 39 (53) | NR | NR | NR | NR | Retrospective analysis of a living cohort |
| Kenet et al27 | USA | 2003-2010 | <1 mo | 633 | NR | NR | NR | NR | NR | NR | 5 (1) | NR | NR | UDC database enrolling babies diagnosed within 1 mo of age |
| Richards et al28 | EHTSB# | 1990-2008 | ≤28 d | 508 | 429 | 78 | 257 (51) | 101 (20) | 149 (29) | NR | NR | NR | NR | Retrospective multicenter study |
| Nazir et al29 | Gulf region** | 1998-2015 | <2 wk | 163 | 163 | 0 | 163 (100) | 0 | 0 | NR | NR | NR | NR | Study with retrospective data (1998-2013) and prospective data (2013-2015) |
| Palomo Bravo et al73 | Spain | 2000-2012 | Perinatal | 88 | 80 | 8 | 42 (48) | 12 (14) | 34 (39) | NR | NR | NR | NR | Retrospective study of consecutively born children followed up for ≥1 y |
| Andersson et al30 | PedNet†† | 2000-2015 | ≤28 d | 926 | 803 | 123 | 786 (85) | 140 (15) | 0 | NR | NR | NR | NR | Prospective study of children consecutively born with ≥1 follow-up visit |
| Yoffe and Buchanan74 | USA | 1977-1987 | Neonatal | 150 | 119 | 31 | NR | NR | NR | NR | NR | NR | NR | Retrospective analysis of a living cohort |
| Klinge et al15 | Germany | 1975-1997 | <1 wk | 744 | 602 | 142 | 507 (68) | 129 (17) | 108 (15) | NR | NR | NR | NR | Survey among HTCs over children born 1975-1997, retrospective ICH assessment |
| Revel-Vilk et al16 | Canada | 1984-2000 | <1 mo | 172 | NR | NR | NR | NR | NR | NR | NR | NR | NR | Retrospective study into lifetime ICH among a living cohort |
| Bladen et al17 | UK | 1987-2013 | Neonatal | 431 | 364 | 67 | 283 (66) | 34 (8) | 107 (25) | NR | NR | NR | NR | Retrospective single-center study |
| Chalmers et al6 | UK | 2003-2015 | <1 mo | 1321 | 1096 | 225 | 655 (50) | 666 nonsevere (50) | NR | NR | NR | NR | UKHCDO, retrospective study of database | |
CVD, cardiovascular disease; HCV, hepatitis C virus; HGDS, Hemophilia Growth and Development Study; HSS, Haemophilia Surveillance System; HTC, hemophilia treatment center; ICD, International Classification of Disease; IHSS, Indiana Haemophilia Surveillance System; Inhib., inhibitor positive; NR, not reported; Proph., prophylaxis; UDC, Universal Data Collection surveillance system; UK, United Kingdom, UKHCDO, United Kingdom Haemophilia Centre Doctors' Organisation.
Austria, Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, UK, Colombia, Czech Republic, Hungary, Poland, Portugal, Russia, and Slovenia.
Austria, Australia, Belgium, Finland, Germany, Italy, Netherlands, Spain, Sweden, and UK.
Austria, Australia, Belgium, Canada, China, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, UK, USA, Israel, and Turkey.
Median instead of mean.
A total of 333 patients were included, history of ICH was available for 309 patients. Numbers for severity and type do not add up because of missing data.
Argentina, Brazil, South Africa, Thailand, Egypt, Singapore, Venezuela, and Iran.
Finland, France, Germany, Italy, Netherlands, Spain, UK, and Slovakia.
Oman, United Arab Emirates, Kuwait, and Saudi Arabia.
Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK, Israel, and Portugal.